Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Angiosarcoma is a challenging subtype of sarcoma as it is a very aggressive tumor, explains Sankhala. There are some chemotherapy drugs such as paclitaxel and doxorubicin that respond very well but recurs and progresses quickly.

According to Sankhala, the discovery of the TRC105 and pazopanib will hopefully achieve prolonged stabilization of the responses in these patients with angiosarcoma, states Sankhala.